Edinburgh Biosciences Showcases Light-Based Cataract Treatment Platform at 100% Optical 2026

At the 100% Optical 2026 meeting, Edinburgh Biosciences introduced the SDS-100, the company’s proprietary system designed to deliver its Photon Protein Modulation (PPM) treatment.

The exhibition provided the first opportunity for many clinicians to see the SDS-100 device in person and learn more about the company’s research into noninvasive approaches to vision loss caused by cataracts.

At the center of the showcase was "Revisyon," Edinburgh Biosciences’ Photon Protein Modulation technology. The platform is being developed as a targeted light-based treatment designed to support earlier intervention in cataract development and potentially expand treatment options beyond traditional surgical pathways.

At the meeting, the Edinburgh Biosciences team presented long-term clinical findings from studies involving more than 240 participants exploring the use of Photon Protein Modulation in cataract care. The presentation offered attendees insight into the scientific foundations, treatment mechanism and emerging clinical observations associated with the technology. The company confirmed that further analysis of the data is ongoing, with peer-reviewed publication expected later this year.

Originally published online on Eyewire+.